← All companies
Monte Rosa Therapeutics, Inc.
GLUE - CIK 0001826457
Market cap$1.39 B
Rank#2397
SEC filings352
The table below shows Monte Rosa Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $141.50M | $121.56M | $111.27M | $85.06M | $57.16M | $24.00M |
| SG&A | $36.38M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.